Depressing AAPL and Geron down, ACTC up on good news

What a depressing market. AAPL down down down to $537.75 on alot of volume 37.7 million shares. The three month avg. is 17.6 million shares. AAPL is still the best company out there, for now, makes you think what in the world is going on. ..................................................................................................................................................................................................................................................................... Geron down to $1.28 I can only hope Dec. will being good results the the last 4 trials. If I will be sitting here crying........................................ ..................................................................................................................................................................................................................................................................... ACTC had good news on was up a little at 0.072. Advanced Cell Tech. announces interim data from its three ongoing macular degeneration trials; no adverse safety issues relating to the transplanted cells have been observed (ACTC) 0.07 +0.00 : Co announced that its upcoming conference call on its third quarter financial results will also provide some representative examples of data being collected from patients in its clinical trials for forms of macular degeneration. The Company has treated 13 patients thus far in its three ongoing trials for dry age-related macular degeneration (dry AMD) and Stargardt's Disease (SMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial cells. The first two trials were initiated in July of 2011. Across the various clinical trial sites, with regular patient follow-up, no adverse safety issues relating to the transplanted cells have been observed. At up to 16 months following treatment, no hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection were observed in any of the 13 patients at any time. At a recent meeting of the various U.S. and U.K. surgeons leading the clinical trials, the Company and surgeons reviewed the data from various patients and discussed next steps and strategies for the existing trials and designs for future phase II and III studies..............................................I still have a good feeling about this company. It's a very, very long shot.............................................. .............................................................................................................................................................................. Good luck in this rigged casino,